All Comments by Douglas Galasko

  1. Cerebrospinal Fluid Neurogranin Correlates with Markers of Neurodegeneration
  2. End of the RoAD for Gantenerumab? Roche Declares Prodromal Alzheimer’s Trial Futile
  3. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
  4. Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease.
  5. NIH Funds Prevention Trials and Translational Studies
  6. Cerebrospinal Fluid Tau Climbs in Aβ Mouse Models
  7. Development and advanced validation of an optimized method for the quantitation of aβ(42) in human cerebrospinal fluid.
  8. APOE {varepsilon}4 Status and Traumatic Brain Injury on the Gridiron or the Battlefield.
  9. In Mice, Oxidative Changes Come Early and Antioxidants Work
  10. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses.
  11. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
  12. Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.
  13. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia.
  14. Dementia screening in primary care: is it time?
  15. Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease.